Meningococcal Vaccine Market by Brands (Menactra, Menveo, Nimenrix, Trumenba, Bexsero, and Others), Types (Bivalent, Quadrivalent, and Others), Age Groups (Infants and Children & Adults), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global meningococcal vaccine market size is estimated to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the owing to the increasing prevalence of meningitis.
Meningococcal vaccines help prevent meningococcal disease, an illness caused by Neisseria meningitidis bacteria. The rising pervasiveness of meningitis is one of the key factors expected to drive the market. Every year around 1.80 million cases of the disease are reported globally, a study published the Centers for Disease Control and Prevention (CDC). At the World Health Assembly by Eastern Mediterranean & African regions, a global program on “Defeating meningitis by 2030” was launched in May 2018 to structure a roadmap for prevention of meningitis by focusing on areas for enhanced and research activities.
Training to healthcare professionals, offering information & support to patients, and involvement of various non-profit organizations in providing funds for research projects are the key factors influencing the market. Around USD 27.0 million investment in scientific researches and 161 research grants awarded by Meningitis Research Foundation as part of its efforts to make people aware and expertise together to face the challenges in prevention of meningitis. Additionally, a vaccine called MenACYW manufactured by Sanofi is in phase III clinical trial and the rapid development of phase III vaccines is one of the main factors positively impacting the market. Moreover, Serum Institute of India Pvt. Ltd. is currently working on a conjugate vaccine to deliver it at an affordable price.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing pervasiveness of meningitis and rising development of vaccines for the disease treatment are major factors expected to drive the market growth.
- Rising government initiatives and regulatory authorities for awareness campaign to control the rising meningitis cases is expected to fuel the market expansion.
- Lack of awareness of the disease among a large number of the global population and in developing countries in particular is estimated to restrain the market growth.
- Adverse reactions of the meningococcal vaccine may affect decision making of a particular treatment, which is expected to hinder the market growth.
Scope of the Report
The report on the global meningococcal vaccine market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Meningococcal Vaccine Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Brands (Menactra, Menveo, Nimenrix, Trumenba, Bexsero, and Others), Types (Bivalent, Quadrivalent, and Others), and Age Groups (Infants and Children & Adults) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Pfizer Inc.; Novartis International AG; Sanofi; Serum Institute of India Ltd.; GlaxoSmithKline plc; and Merck & Co., Inc. |
Market Segment Insights
Bexsero segment is expected to grow at a rapid pace
Based on brands, the global meningococcal vaccine market is divided into menactra, menveo, nimenrix, trumenba, bexsero, and others. The bexsero segment is expected to grow at a rapid pace during the forecast period owing to low cost and successful commercialization of the vaccine. However, the others segment is anticipated to expand at a rapid pace during the forecast period owing to increase in government initiatives for the development of meningococcal vaccine and increasing demand for the vaccine.
Quadrivalent segment is projected to expand at a considerable CAGR
On the basis of types, the market is divided into bivalent, quadrivalent, and others. The quadrivalent segment is projected to account for a key share of the market due to widely used brands such as Nimenrix, Menveo, and Menactra along with the approval of new vaccines to prevent people from the disease. Meanwhile, the others segment is anticipated to expand at a rapid CAGR during the forecast period owing to the presence of main market players to develop innovative products and vaccine in both developing and developed countries.
Infants segment is expected to expand at a robust growth rate
Based on age groups, the global meningococcal vaccine market is bifurcated into infants (0 to 2 years) and children & adults (2 years & above). The infants segment is expected to expand at a robust growth rate in the coming years owing to increasing number of prevalence of meningitis among the age group. On the other hand, the children & adults (2 years & above) segment is attributed to exhibit a high CAGR during the forecast period due to rise in number of government approvals and acceptance for the vaccine of children and adults.
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key share of the market owing to high investments in research and development coupled with increasing favorable support and recommendations by governments in the region. Meanwhile, the market of Asia Pacific is anticipated to expand at a substantial CAGR during the forecast period due to rising pediatric population and increasing number of incidences among them in the region.
Segments
Segments Covered in the ReportThe global meningococcal vaccine market has been segmented on the basis of
Brands
- Menactra
- Menveo
- Nimenrix
- Trumenba
- Bexsero
- Others
- Bivalent
- Quadrivalent
- Others
- Infants (0 to 2 Years)
- Children & Adults (2 years & above)
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Pfizer Inc.
- Novartis International AG
- Sanofi
- Serum Institute of India Ltd.
- GlaxoSmithKline plc.
- Merck & Co., Inc.
Competitive Landscape
Key players competing in the global meningococcal vaccine market are Pfizer Inc.; Novartis International AG; Sanofi; Serum Institute of India Ltd.; GlaxoSmithKline plc; and Merck & Co., Inc. One of the key development of the market can be traced back to the launching of a new molecular vaccine named PF-06886992 was developed by Pfizer for Serogroups ABCWY meningococcal infections, which is in Phase II clinical trials currently.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Meningococcal Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Meningococcal Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Meningococcal Vaccine Market - Supply Chain
4.5. Global Meningococcal Vaccine Market Forecast
4.5.1. Meningococcal Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Meningococcal Vaccine Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Meningococcal Vaccine Market Absolute $ Opportunity
5. Global Meningococcal Vaccine Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Meningococcal Vaccine Market Size and Volume Forecast by Types
5.3.1. Bivalent Quadrivalent Others
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Meningococcal Vaccine Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Meningococcal Vaccine Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Meningococcal Vaccine Demand Share Forecast, 2019-2026
7. North America Meningococcal Vaccine Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Meningococcal Vaccine Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Meningococcal Vaccine Market Size and Volume Forecast by Types
7.4.1. Bivalent Quadrivalent Others
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Meningococcal Vaccine Demand Share Forecast, 2019-2026
8. Latin America Meningococcal Vaccine Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Meningococcal Vaccine Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Meningococcal Vaccine Market Size and Volume Forecast by Types
8.4.1. Bivalent Quadrivalent Others
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Meningococcal Vaccine Demand Share Forecast, 2019-2026
9. Europe Meningococcal Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Meningococcal Vaccine Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Meningococcal Vaccine Market Size and Volume Forecast by Types
9.4.1. Bivalent Quadrivalent Others
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Meningococcal Vaccine Demand Share Forecast, 2019-2026
10. Asia Pacific Meningococcal Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Meningococcal Vaccine Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Meningococcal Vaccine Market Size and Volume Forecast by Types
10.4.1. Bivalent Quadrivalent Others
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Meningococcal Vaccine Demand Share Forecast, 2019-2026
11. Middle East & Africa Meningococcal Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Meningococcal Vaccine Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Meningococcal Vaccine Market Size and Volume Forecast by Types
11.4.1. Bivalent Quadrivalent Others
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Meningococcal Vaccine Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Meningococcal Vaccine Market: Market Share Analysis
12.2. Meningococcal Vaccine Distributors and Customers
12.3. Meningococcal Vaccine Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Pfizer Inc. Novartis International AG Sanofi Serum Institute of India Ltd. GlaxoSmithKline plc. Merck & Co., Inc.
The global meningococcal vaccine market has been segmented on the basis of
Brands
- Menactra
- Menveo
- Nimenrix
- Trumenba
- Bexsero
- Others
- Bivalent
- Quadrivalent
- Others
- Infants (0 to 2 Years)
- Children & Adults (2 years & above)
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Pfizer Inc.
- Novartis International AG
- Sanofi
- Serum Institute of India Ltd.
- GlaxoSmithKline plc.
- Merck & Co., Inc.
Key players competing in the global meningococcal vaccine market are Pfizer Inc.; Novartis International AG; Sanofi; Serum Institute of India Ltd.; GlaxoSmithKline plc; and Merck & Co., Inc. One of the key development of the market can be traced back to the launching of a new molecular vaccine named PF-06886992 was developed by Pfizer for Serogroups ABCWY meningococcal infections, which is in Phase II clinical trials currently.
Our Clients
Related Reports
Some other reports from this category!
